Author: Florian Stieglitz, Consultant, Market Access
From Proposal to Political Agreement
Nearly three years after the European Commission presented its proposal to revise EU pharmaceutical legislation, the European institutions have reached a political agreement through trilogue negotiations under the Danish Council Presidency. Although the final legal texts are still pending, the core architecture of the reform is now defined. The package represents a structural redesign of how incentives, obligations, and regulatory processes interact across the lifecycle of medicines in Europe.
Regulatory Protection and Incentive Structure
The agreement establishes a clear and more deterministic framework for regulatory protection. Regulatory data protection is set at eight years as a fixed baseline. This is complemented by one year of market protection, with the possibility of a twelve-month extension under defined conditions, such as addressing unmet medical need or fulfilling specific development and launch requirements. A further year of market protection may be granted for a new therapeutic indication. Overall, total regulatory protection is capped at eleven years, introducing a firm upper boundary to lifecycle incentives.
For orphan medicinal products, market exclusivity is set at nine years, with two additional years available for so-called “breakthrough” products targeting diseases with particularly high unmet medical need. Repurposing is addressed through a one-time grant of four years of data protection, limited to medicines that either never benefited from such protection or whose original protection expired more than 25 years ago.
Antimicrobial Resistance and Public Health Priorities
Antimicrobial resistance is treated as a distinct policy domain. Incentives for priority antibiotics remain in place through transferable exclusivity vouchers, granting an additional year of data protection outside the general eleven-year cap. These incentives are constrained by volume and revenue thresholds to prevent application to high-revenue products. In parallel, obligations are expanded: antimicrobial products require mandatory stewardship plans, reinforced environmental risk assessments including resistance development, and prescription-only status across the EU, with limited national flexibility for topical use.
Competition, Access, and Supply Security
The reform significantly expands the Bolar exemption. Activities related to studies, regulatory submissions, HTA procedures, pricing and reimbursement processes, and preparatory manufacturing and logistics are no longer considered patent or SPC infringements, provided no commercial sale occurs during the protection period. Regulatory and reimbursement decisions may not be refused solely due to the intellectual property status of the reference product.
Supply security becomes a core regulatory objective. Marketing authorisation holders must notify authorities of foreseeable supply interruptions at least six months in advance where possible. Shortage-prevention plans are mandatory for prescription medicines, with further detail to be specified through delegated acts. The EMA gains stronger coordination and monitoring responsibilities for critical shortages.
Procedural and Regulatory Modernisation
The agreement accelerates and standardises regulatory procedures. CHMP assessment timelines are shortened from 210 to 180 days. Marketing authorisation applications move to a unified electronic format and are granted for unlimited duration by default, subject to safety-based restrictions. Electronic product information is introduced alongside paper leaflets, with Member States permitted to waive the paper requirement. Regulatory sandboxes allow controlled flexibility for innovative products that cannot fully comply with existing rules due to scientific or technical constraints.
Timeline and Implementation
The political agreement now moves into technical consolidation, legal review, and translation, followed by formal adoption by the Council and the European Parliament. Entry into force is expected in Q2 2026, with application beginning around mid-2028. Delegated and implementing acts will further shape operational details.
Strategic Implications
The EU pharmaceutical package does not introduce isolated adjustments. It restructures the logic of incentives, access obligations, environmental accountability, and supply security across Europe. The result is a more rule-defined and conditional environment, in which early strategic alignment between development, evidence generation, and market access becomes increasingly critical. Continuous interpretation of regulatory signals will be required as the framework moves from political agreement to operational reality.
Staying current on these developments and understanding their strategic implications is essential. Kintiga follows these changes closely, ensuring that clients remain informed and retain a clear, forward-looking strategic perspective on how regulatory reform translates into market access and pricing consequences.
Sources
- ‘Pharma package’: Council and Parliament reach a deal on new rules for a fairer and more competitiv…
- Background note: pharmaceutical package provisional agreement elements | News | European Parliament
- Deal on comprehensive reform of EU pharmaceutical legislation | News | European Parliament
- Kommission begrüßt politische Einigung über umfassende Reform der EU-Arzneimittelvorschriften
